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Background: Talin-1 is a cytoskeletal protein that plays an important role in tumourgenesis, migration and
metastasis in several malignant tumors. The aim of this study was to evaluate the expression and prognostic value
of Talin-1 in nasopharyngeal carcinoma (NPC).
Methods: Talin-1 mRNA and protein expression were examined in NPC cell lines and clinical nasopharyngeal
tissues by quantitative RT-PCR, agarose gel electrophoresis and western blotting. The expression of Talin-1 was
analyzed by immunohistochemical staining in 233 paraffin-embedded NPC specimens with clinical follow-up data
and cox regression analysis was used to identify independent prognostic factors. The functional role of Talin-1 in
NPC cell lines was evaluated by small interfering RNA-mediated depletion of the protein followed by the wound
healing and transwell invasion assays.
Results: The expression of Talin-1 was significantly upregulated in most NPC cell lines and clinical tissues at both the
mRNA and protein levels. High expression of Talin-1 was significantly associated with distant metastasis (P = 0.001) and
patient death (P = 0.001). In addition, high expression of Talin-1 was associated with significantly poorer overall survival
(OS: HR, 2.15; 95% CI, 1.28-3.63; P = 0.003) and poorer distant metastasis-free survival (DMFS: HR, 2.39; 95% CI, 1.38-4.15;
P = 0.001). Cox regression analysis indicated that high expression of Talin-1 and TNM stage were independent
prognostic indicators (both P < 0.05). Stratified analysis demonstrated that high expression of Talin-1 was associated
with significantly poorer survival in patients with advanced stage disease (stage III-IV, HR, 1.91; 95% CI, 1.09-3.35; P = 0.02
for OS and HR, 2.22; 95% CI, 1.24-3.99; P = 0.006 for DMFS). Furthermore, the depletion of Talin-1 suppressed the
migratory and invasive ability of NPC cells in vitro.
Conclusions: Our data demonstrate that high expression of Talin-1 is associated with significantly poorer OS and
poorer DMFS in NPC and depletion of Talin-1 expression inhibited NPC cell migration and invasion. Talin-1 may
serve as novel prognostic biomarker in NPC.
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Nasopharyngeal carcinoma (NPC) is rare in most popu-
lations throughout the world, but is relatively common
in Southern China and Southeast Asia where the inci-
dence is as high as 20 to 50 per 100,000 person-years
[1-4]. There were an estimated 84,400 incident cases of
NPC and 51,600 NPC-related deaths in 2008 according
to data from the International Agency for Research on
Cancer [5]. Due to anatomic constraints and its high ra-
diosensitivity, early-stage NPC is typically treated using
radiotherapy, whereas chemoradiotherapy is the stand-
ard treatment for advanced NPC [6].
Currently, the clinical TNM (tumor, node, metastasis)
staging system for NPC is most frequently used to esti-
mate prognosis. However, large variations are observed in
the clinical outcomes of patients with the same stage of
disease who undergo similar therapies, indicating that the
TNM staging system alone is inadequate for accurately
predicting prognosis [7,8]. With progress in molecular
biology, the identification of molecular biomarkers may
provide additional value to prognostic predictions. In
recent years, several molecular biomarkers have been
identified to be associated with prognosis in NPC, such
as breast cancer metastasis suppressor 1 (BRMS1),
metastasis-associated protein 1 (MTA1), Dicer 11,
centromere protein-H (CENP-H) and cancerous inhibi-
tor of protein phosphatase 2A (CIP2A) [9-13]; however,
prognostic prediction in NPC remains extremely poor
[14]. Therefore, the discovery of novel biomarkers that
could be utilized as more effective prognostic predic-
tors would be of significant clinical value and further-
more could help to enable individualized treatment of
patients with NPC.
Talin-1, a large 270 kDa cytoskeletal protein that con-
tains 2541 amino acids, is mainly expressed in the kidney,
liver, spleen, stomach, lung and vascular smooth muscle
and plays an essential role in integrin activation [15]. Pre-
vious studies demonstrated that the expression of Talin-1
was highly associated with endometrioid carcinoma, oral
squamous cell carcinoma (OSCC), prostate cancer and he-
patocellular carcinoma [16-20]. In addition, Talin-1 can
promote cancer cell adhesion, migration and invasion, and
may represent a diagnostic marker of aggressive pheno-
types and a potential therapeutic target for prostate cancer
and OSCC [17,18]. To date, however, the expression levels
and clinical significance of Talin-1 in NPC remain largely
unknown.
In the present study, we examined both the mRNA and
protein expression levels of Talin-1 in NPC cell lines and
clinical tissue samples, and also analyzed the association
between Talin-1 expression and the clinical characteristics
of a cohort of patients with NPC from Guangdong Prov-
ince, an area of China where the population have a high
risk of NPC. Furthermore, we evaluated the prognosticvalue of Talin-1, in order to develop a more personalized
therapy for NPC.
Methods
Cell lines and cell culture
Human NPC cell lines (CNE-1, CNE-2, SUNE-1, C666-1,
HNE1 and HONE1) were cultured in RPMI-1640 (Invitro-
gen, Carlsbad, CA, USA) medium supplemented with 10%
fetal bovine serum. The immortalized nasopharyngeal
epithelial cell line (NP69) was cultured in keratinocyte/
serum-free medium (Invitrogen) supplemented with
bovine pituitary extract, as previously described [12].
All cell lines were incubated at 37°C in a 5% CO2
incubator.
Patients and tissue specimens
Eight freshly-frozen NPC specimens and six normal
nasopharyngeal epithelium samples were obtained from
Sun Yat-sen University Cancer Center. In addition, a
total of 233 pretreatment paraffin-embedded NPC speci-
mens were collected from our hospital between January
2003 and February 2006; none of the 233 NPC patients
had received radiotherapy or chemotherapy before biopsy.
The clinical characteristics of all patients were recorded
(Table 1). All patients were treated with conventional two-
dimensional radiotherapy, and patients with stage III-IV
disease also received platinum-based concurrent chemo-
therapy [21,22]. The median follow-up time for the entire
cohort was 63.2 months (range, 5.2-91.87). The following
end points (time to the first defining event) were assessed:
5-year overall survival (OS) and distant metastasis-free
survival (DMFS). This study was approved by the Institu-
tional Ethical Review Board of Sun Yat-sen University
Cancer Center, and written informed consent was ob-
tained from each patient.
RNA extraction, reverse transcription, quantitative RT-PCR
and agarose gel electrophoresis
Total RNA was extracted from the cell lines using TRIzol
reagent (Life Technologies, Grand Island, NY, USA). The
extracted RNA (2 μg) was reverse transcribed using
random primers (Promega, Madison, WI, USA) and
M-MLV reverse transcriptase (Promega) for 60 min at
37°C and then 15 min at 70°C, and the product was
stored at -20°C until use. Quantitative RT-PCR was
performed on the PRISM 7900HT sequence detection
system (Applied Biosystems, Carlsbad, CA, USA) in 15 μL
reactions containing 0.5 μL of reverse transcription prod-
uct, 7.5 μL of Platinum SYBR Green qPCR SuperMix-UDG
reagents (Invitrogen), 1.5 μL of each PCR forward primer
and reverse primer (final concentration, 2.5 μM), and
5.5 μL of ddH2O. The reactions were pre-incubated at 95°C
for 10 min, followed by 40 cycles of denaturation at 95°C
for 30 s and annealing/extension at 60°C for 1 min, then
Table 1 Clinical characteristics of the patients with
nasopharyngeal carcinoma stratified by low and high
expression of Talin-1
Characteristic No. of patients Expression of talin-1 P-value*
Low, n (%) High, n (%)
Age
≤45 years 114 87 (76.3) 27 (23.7) 0.09
>45 years 119 79 (66.4) 40 (33.6)
Sex
Male 169 124 (73.4) 45 (26.6) 0.24
Female 64 42 (65.6) 22 (34.4)
WHO type
I + II 8 4 (50.0) 4 (50.0) 0.23
III 225 162 (72.0) 63 (28.0)
VCA-IgA
<1:80 35 27 (77.1) 8(22.9) 0.40
≥1:80 198 139 (70.2) 59(29.8)
EA-IgA
<1:10 57 42 (73.7) 15 (26.3) 0.64
≥1:10 176 124 (70.5) 52 (29.5)
T Stage
T1-T2 113 85 (75.2) 28 (24.8) 0.19
T3-T4 120 81 (67.5) 39 (32.5)
N Stage
N0-N1 143 103 (72.0) 40 (28.0) 0.74
N2-N3 90 63 (70.0) 27 (30.0)
TNM stage
I-II 72 56 (77.8) 16 (22.2) 0.14
III-IV 161 110 (68.3) 51(31.7)
Locoregional failure
Yes 39 23 (59.0) 16 (41.0) 0.06
No 194 143 (73.7) 51 (26.3)
Distant metastasis
Yes 51 27 (52.9) 24 (47.1) 0.001
No 182 139 (76.4) 43 (23.6)
Death
Yes 57 31 (54.4) 26 (45.6) 0.001
No 176 135 (76.7) 41 (23.3)
Abbreviations: WHO: World Health Organization; VCA-IgA: viral capsid antigen
immunoglobulin A; EA-IgA: early antigen immunoglobulin A. P-values* were
calculated using the chi-square test or Fisher’s exact test.
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following PCR primers were used: Talin-1 forward, 5′-CTG
GAGGCAACCACAGAAC-3′ and Talin-1 reverse, 5′-GT
GGCTCTGGGGAACAGA-3′; glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) forward, 5′-CTCCTCCTGTTC
GACAGTCAGC-3′ and GAPDH reverse, 5′-CCCAATAC
GACCAAATCCGTT -3′. All of the assays were performedin triplicate, and reactions containing either no template or
no reverse transcriptase were used as negative controls.
GAPDH was used as the normalization control. Agarose
gel electrophoresis was performed to examine the mRNA
expression level of Talin-1. PCR amplications were per-
formed using the GoTaq Green Master Mix kit (Promega,
USA) and PCR cycling conditions were as follows: 95°C for
2 min, followed by 27 cycles of 95°C for 30 s, 53°C for 30 s
and 72°C for 8 s, then extension at 72°C for 5 min (Biorad,
S1000 Thermal Cycler, USA). PCR products were checked
by 1.5% agarose gel electrophoresis.
Western blotting
Total proteins were extracted using sample buffer
(62.5 mmol/L Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
and 5% 2-β-mercaptoethanol), and the protein concen-
tration was quantified using the Pierce® BCA Protein
Assay Kit (Thermo Scientific, Rockford, IL, USA). Total
proteins were separated on 6% SDS-PAGE gels and
transferred onto polyvinylidene fluoride membranes
(Millipore, Billerica, MA, USA). The membranes were
blocked with 5% skimmed-milk powder in Tris buffered
saline with tween-20 (TBS-T), incubated with mouse
monoclonal anti-Talin-1 (clone 1A11) antibody (1:200;
Abnova, Taipei, Taiwan), then incubated with anti-mouse
IgG secondary antibody (1:5,000; Sigma, St. Louis, MO,
USA). The bands were detected by enhanced chemilumin-
escence; α-tubulin antibody (1:5,000; Epitomics) was used
as a loading control.
Immunohistochemical staining
The expression of Talin-1 in the sections from the 233
paraffin-embedded NPC specimens was examined by
immunohistochemical staining, as described previously
[23]. Briefly, the tissue blocks were cut into 5 μm-thick
sections, followed by deparaffinization and rehydration.
The sections were microwaved for antigen retrieval in
EDTA buffer, and 3% hydrogen peroxide was used to
quench endogenous peroxidase activity. Non-specific
binding was blocked using 1% bovine serum albumin.
The sections were then incubated overnight at 4°C with
mouse monoclonal anti-Talin-1 (clone 1A11) antibody
(1:100; Abnova); normal goat serum was used as a negative
control. After rinsing, the sections were incubated with bi-
otinylated secondary antibody bound to a streptavidin-
horseradish peroxidase complex. The bound antibody was
visualized by adding 3,3-diaminobenzidine, and then the
sections were counterstained with hematoxylin, dehydrated
and mounted.
The sections were scored independently by two pa-
thologists, and any disagreements were resolved by con-
sensus. Both the proportion of positively-stained tumor
cells and the intensity of staining were assessed [23,24].
The proportion of positive tumor cells was scored as
Xu et al. BMC Cancer  (2015) 15:332 Page 4 of 10follows: 1 (<10%), 2 (10-35%), 3 (35-70%), and 4 (>70%).
The intensity of staining was graded on a scale from 0 to
3 as follows: 0 (no staining), 1 (weak staining, light yel-
low), 2 (moderate staining, yellow brown), and 3 (strong
staining, brown). The staining index was calculated as
the product of the staining intensity score and the pro-
portion of positive tumor cells; using this method,
staining index scores of 0, 1, 2, 3, 4, 6, 8, 9 or 12 were
possible. The optimal cutoff value for high and low ex-
pression was selected based on a receiver operating
characteristic (ROC) curve analysis, as previously de-
scribed [9,25-27]. The best cutoff score of Talin-1 was
5. Therefore, a staining index score of < 5 was used to
define NPC with low Talin-1 expression and a staining
index score of > 5 was designated as high Talin-1
expression.Oligonucleotide transfection
CNE-2 or SUNE-1 cells were seeded into six-well plates
24 h prior to transfection. The Talin-1-silencing oligonu-
cleotides (siTalin-1) or the respective controls (siCont)
(GenePharma, Shanghai, China),) were transfected into
the cells at a final concentration of 100 nmol/L using
Lipofectamine™ 2000 (Invitrogen). The cells were har-
vested 48 h after transfection for the specified assays.
Wound healing assay
For the wound healing assay, transfected CNE-2 or
SUNE-1 cells were seeded into 6-well plates. After
serum starvation in serum-free media for 24 h, an artifi-
cial wound was created on the confluent cell monolayer
using a standard 200 μl plastic pipette tip. Cells migrated
into the scratch area as single cells from the confluent
sides; the width of the scratch gap was viewed under an
inverted microscope and photographed at 0 h and 24 h.
Three replicate wells from a six-well plate were used for
this experiment.
Transwell invasion assays
Invasion assays were performed in Transwell chambers
(Corning, Steuben County, New York, USA) coated with
Matrigel (BD Biosciences) on the upper surface of mem-
brane with 8 μm-pore size. In brief, transfected CNE-2
or SUNE-1 cells were harvested, suspended in serum-
free medium and 1 × 105 transfected cells were plated
into the upper chamber for the invasion assays, and
media supplemented with 10% FBS was placed into the
lower chamber. After incubation for 24 h, the cells that
had invaded through the membrane to the lower surface
were fixed, stained and counted under an inverted
microscope. Five random fields of view were analyzed
for each chamber; three independent experiments were
conducted for each assay.Statistical analysis
The Chi-square test or Fisher’s exact test were used to
analyze the relationships between Talin-1 protein expres-
sion and clinical characteristics. Talin-1 mRNA expression
levels in normal nasopharyngeal epithelial tissues and
NPC tissues were analyzed using the Student’s t-test. For
functional analyses, data were presented as mean ± stand-
ard deviation and Student’s t-tests were used to determine
the significance of the differences between two groups.
The Kaplan-Meier method was used to estimate OS and
DMFS, and the differences were compared using the log-
rank test. A Cox proportional hazards regression analysis
with backward stepwise selection was used to identify
independent predictive factors for OS and DMFS and
calculate hazard ratio (HR) values. The Talin-1 expres-
sion level, age, sex, clinical stage, WHO type, VCA-IgA
and EA-IgA were included as covariates. All statistical
analyses were performed using SPSS 16.0 software
(SPSS, Chicago, IL, USA); two-tailed P-values < 0.05
were considered significant.
Results
Talin-1 is upregulated in NPC cells and tissues
The mRNA and protein expression levels of Talin-1 in the
normal nasopharyngeal epithelial cell line NP69 and NPC
cell lines were assessed by quantitative RT-PCR, agarose
gel electrophoresis and Western blot analysis. Compared
to NP69 cells, Talin-1 was significantly upregulated in all
NPC cell lines tested at both the mRNA and protein levels,
except for HNE1 cells (Figure 1A, C, E). Furthermore, we
assessed the mRNA and protein levels of Talin-1 in eight
freshly-frozen NPC tissues and six normal nasopharyngeal
epithelial tissues, and observed that both Talin-1 mRNA
and protein were expressed at considerably higher levels in
the NPC tissues (Figure 1B, D, F). These results suggest
that overexpression of Talin-1 may be involved in the pro-
gression of NPC.
Associations between Talin-1 expression and the clinico-
pathological features of NPC
To identify the associations between Talin-1 protein ex-
pression and the clinical features of patients with NPC,
we analyzed Talin-1 protein expression in a set of 233
paraffin-embedded NPC tissue samples using immuno-
histochemistry. Representative images of Talin-1 immu-
nohistochemical staining in NPC tissues are shown in
Figure 2A-D. Positive staining for Talin-1 was mainly
observed in the cytoplasm of the NPC cells. Talin-1 ex-
pression was found in 182 out of 233 (78.1%) NPCs.
Using a staining index of 5 as the cutoff point in the 233
patients with NPC examined, we classified 166 (71.2%)
patients with low expression of Talin-1 and 67 (28.8%)
patients with high expression of Talin-1. As shown in
Table 1, high Talin-1 expression was significantly associated
Figure 1 Talin-1 mRNA and protein expression in NPC cell lines and tissues. (A and B) Quantitative RT-PCR analysis of Talin-1 expression levels in
the NP69 and NPC cell lines and in NPC (n = 8) and normal nasopharyngeal epithelial tissues (n = 6). (C and D) Agarose gel electrophoresis of
Talin-1 expression in the NP69 and NPC cell lines and in NPC (n = 8) and normal nasopharyngeal epithelial tissues (n = 6). (E and F) Western blotting
analysis of Talin-1 protein expression in the NP69 and NPC cell lines and in NPC and normal nasopharyngeal epithelial tissues. Data is presented as
mean ± SD values; the P-value was calculated using the Student’s t-test.
Figure 2 Immunohistochemical analysis of Talin-1 protein expression in
clinical nasopharyngeal carcinoma tissues. Talin-1 protein expression
was mainly localized to the cytoplasm of NPC cells. Representative
images of (A) negative staining, (B) weak staining (light yellow),
(C) moderate staining (yellow brown) and (D) strong staining (brown)
in clinical NPC specimens. All images are 400 × .
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(P = 0.001). However, there were no significant associa-
tions between Talin-1 expression and other clinical fea-
tures, such as age, sex, WHO type, VCA-IgA, EA-IgA,
clinical stage (T stage, N stage or TNM stage) or locore-
gional failure (P > 0.05).
High expression of Talin-1 is associated with a poor prog-
nosis in NPC
The relationship between Talin-1 expression and sur-
vival in NPC was assessed using Kaplan-Meier analysis
and the log-rank test. As shown in Figure 3, high
Talin-1 expression was associated with significantly
poorer OS (HR, 2.15; 95% CI, 1.28-3.63; P = 0.003) and
poorer DMFS (HR, 2.39; 95% CI, 1.38-4.15; P = 0.001;
Figure 3A-B). The cumulative 5-year survival rate for
the low Talin-1 expression group was 78.8% (95% CI,
75.0-82.5) compared to only 68.4% (95% CI, 61.0-75.8)
for the high Talin-1 expression group.
Furthermore, stratified analysis indicated that in the
subgroup with early-stage NPC (stage I-II, n = 72), the
differences in OS and DMFS between patients with high
or low Talin-1 expression were not significant (P = 0.25
and P = 0.47, respectively; Figure 4A). However, in the
advanced disease subgroup (stage III-IV, n = 161), pa-
tients with high Talin-1 expression had significantly
poorer OS (HR, 1.91; 95% CI, 1.09-3.35; P = 0.02) and
Figure 3 Overall and distant metastasis-free survival for patients stratified by low and high expression of Talin-1. Kaplan-Meier (A) overall survival and
(B) distant metastasis-free survival curves for patients with nasopharyngeal carcinoma (n= 233) stratified by low and high expression of Talin-1. HR, hazard
ratio, and CI, confidence interval; HR values were calculated using unadjusted Cox regression analyses; P-values were calculated using the log-rank test.
Xu et al. BMC Cancer  (2015) 15:332 Page 6 of 10poorer DMFS (HR, 2.22; 95% CI, 1.24-3.99; P = 0.006)
than those with low Talin-1 expression (Figure 4B).
These results suggest that high expression of Talin-1 is
associated with a poorer prognosis in NPC, especially in
patients with advanced disease (stage III-IV).
High expression of Talin-1 is an independent prognostic
factor in NPC
Univariate and multivariate Cox regression analyses
were carried out to investigate the effect of different
clinical variables, including Talin-1 expression, TNM
stage, age, sex, WHO type, VCA-IgA and EA-IgA, on
OS and DMFS. As shown in Table 2, univariateFigure 4 Upregulation of Talin-1 is associated with poor survival in advanced
curves for patients with (A) Stage I-II (n= 72) and (B) Stage III-IV (n = 161) naso
values were calculated using unadjusted Cox regression analyses; P-values weanalyses indicated that high Talin-1 expression was as-
sociated with significantly poorer OS and poorer
DMFS (P = 0.004 and 0.002, respectively) compared to
low Talin-1 expression. In addition, advanced stage
disease (stage III-IV) was associated with significantly
poorer OS and poorer DMFS (P = 0.003 and 0.002, re-
spectively) compared to early stage disease (stage I-II).
However, age, sex, WHO type, VCA-IgA and EA-IgA
had no significant impact on OS or DMFS (all P > 0.05).
Furthermore, multivariate analyses confirmed that high
expression of Talin-1 and TNM stage were independent
prognostic indicators associated with OS and DMFS in
NPC (both P < 0.05).nasopharyngeal carcinoma. Overall and distant metastasis-free survival
pharyngeal carcinoma. Hazard ratio (HR) and confidence interval (CI)
re calculated using the log-rank test.
Table 2 Univariate and multivariate cox regression analyses of prognostic factors in nasopharyngeal carcinoma
Univariate analysis Multivariate analysis
Variable HR 95% CI P-value* HR 95% CI P-value*
Overall survival
Talin-1 expression (high vs. low) 2.15 1.28-3.63 0.004 1.87 1.10-3.16 0.02
TNM stage (III-IV vs. I-II) 3.06 1.45-6.47 0.003 2.97 1.40-6.29 0.005
Age (≥45 years vs. <45 years) 1.63 0.96-2.78 0.07
Sex (male vs. female) 1.57 0.83-2.96 0.17
WHO Type (III vs. I-II) 0.63 0.20-2.03 0.44
VCA-IgA (≥1:80 vs. < 1:80) 1.50 0.64-3.49 0.35
EA-IgA (≥1:10 vs. < 1:10) 1.04 0.56-1.93 0.90
Distant metastasis-free survival
Talin-1 expression (high vs. low) 2.39 1.38-4.15 0.002 2.18 1.25-3.78 0.006
TNM stage (III-IV vs. I-II) 3.78 1.61-8.86 0.002 3.48 1.48-8.17 0.004
Age (≥45 years vs. < 45 years) 1.58 0.90-2.78 0.11
Sex (male vs. female) 1.51 0.77-2.94 0.23
WHO Type (III vs. I-II) 0.54 0.17-1.73 0.30
VCA-IgA (≥1:80 vs. < 1:80) 1.10 0.50-2.45 0.81
EA-IgA (≥1:10 vs. < 1:10) 1.30 0.65-2.60 0.45
Abbreviations: WHO: World Health Organization; VCA-IgA: viral capsid antigen immunoglobulin A; EA-IgA: early antigen immunoglobulin A. P-values* were
calculated using univariate and multivariate cox regression analyses.
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migration and invasion in vitro
To investigate the effects of aberrant expression of
Talin-1 on the migratory and invasive ability of NPC
cells, CNE-2 and SUNE-1 cells were transfected with
siTalin-1 or siCont. Figures 5A showed that Talin-1 pro-
tein levels were significantly reduced by transfection of
siTalin-1. The wound healing assay demonstrated that
the migratory ability of CNE-2 and SUNE-1 cells trans-
fected with siTalin-1 was significantly lower than those
of cells transfected with siCont (Figure 5B). In addition,
the Transwell invasion assay showed that the invasive
ability of NPC cells transfected with siTalin-1 was sig-
nificantly lower than those of cells transfected with
siCont (Figure 5C; *P < 0.01). These results indicate that
Talin-1 depletion significantly reduces the migratory and
invasive ability of NPC cells in vitro.
Discussion
The clinical prognosis of patients with NPC has improved
significantly with recent advances in diagnostic technolo-
gies and therapeutic interventions. However, patients with
the same clinical stage of NPC still have varying clinical
outcomes when receiving identical therapeutic interven-
tions. Therefore, it is particularly important to identify
novel biomarkers that could more effectively predict prog-
nosis and further help to achieve individualized treatment
of patients with NPC. The present study demonstrates
that Talin-1 is upregulated in NPC at both the mRNAand protein levels, and that high expression of Talin-1
is associated with a significantly poorer prognosis in
patients with NPC. In addition, Talin-1 was identified
as an independent prognostic indicator in multivariate
analysis, indicating that Talin-1 may serve as a novel
prognostic biomarker to guide clinical practice and re-
search on NPC.
Talin-1 is a cytoskeletal protein that acts as a key
adaptor protein to regulate integrin conformation and
cell migration, and has been shown to play an important
role in promoting tumor cell adhesion, migration and in-
vasion in different types of cancer. Previous studies
showed that high expression of Talin-1 was associated
with a poor clinical prognosis in OSCC [17,28]. In
addition, Sakamoto et al. reported that Talin-1 was sig-
nificantly upregulated in primary tumors and metastatic
prostate cancer compared with the normal prostate
gland [18]. Furthermore, higher expression of Talin-1
was observed in triple-negative breast cancer cell lines,
and low Talin-1 expression was a prognostic marker for
better outcome after cytotoxic chemotherapy [29]. To-
gether, these studies indicate that Talin-1 may serve as a
potential diagnostic and prognostic marker of aggressive
phenotypes and may represent a potential therapeutic
target for various types of cancer.
In this study, the Talin-1 expression was found in 182
out of 233 (78.1%) NPCs and the percent of Talin-1
overexpression was 28.8%. Lai MT et al. revealed that
the Talin-1 expression was found in 101 out of 163
Figure 5 Talin-1 depletion had significant effect on the NPC cell migration and invasion in vitro. (A) Talin-1 protein expression by western blotting after
transfection with siTalin-1 or siCont. (B) Representative images of the wound healing assay of CNE-2 and SUNE-1 cells transfected with siTalin-1 or
siCont. (C) Representative images (left) and quantification (right) of the Transwell invasion assay of CNE-2 and SUNE-1 cells transfected with siTalin-1 or
siCont. Values are mean ± SD; *P < 0.01.
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expression was 19.6% [17]. The above results showed
that the expression of Talin-1 were higher in NPC than
that in oral cavity cancer. However, Talin-1 expression in
hepatocellular carcinoma (HCC) was controversial. For
example, Kanamori et al. found that Talin-1 was up-
regulated in HCC (60.4%) [20]. On the other hand,
Zhang et al. proved that Talin-1 was down-regulated in
HCC liver tissues [19]. Therefore, we think that the ex-
pression of Talin-1 has tissue-specificity and further
studies are needed to explore the role of Talin-1 in dif-
ferent cancers. In addition, we observed that high Talin-
1 expression was significantly associated with distant
metastasis and patient death, but not with locoregional
failure. These results suggest that overexpression of
Talin-1 may be involved in the progression of NPC.
It is well-recognized that local control of NPC improved
significantly with the advent of intensity-modulated radio-
therapy, and that the majority of treatment failures and
deaths in patients with NPC are currently attributable to
distant metastasis [30]. Therefore, it is vital to detect
metastasis-associated biomarkers that can effectively dis-
tinguish patients with NPC who are at a high risk of metas-
tasis at the time of diagnosis. Integrin signaling plays a
crucial role in cell invasion and migration, and a variety of
extracellular matrix (ECM)-remodeling factors that maycontribute to these processes have been identified [31-33].
As a focal adhesion complex protein that regulates integrin
interactions with the ECM, Talin-1 has been identified as a
novel regulator of the invasive and metastatic potential of
tumor cells, as overexpression of Talin-1 significantly en-
hanced the migration and invasion of prostate cancer and
OSCC cells in vitro, and was associated with advanced
tumour stage and poorer clinical outcome [17,18]. In the
present study, the wound healing assay and the transwell
invasion assay showed that Talin-1 depletion could signifi-
cantly reduce the migratory and invasive ability of NPC
cells in vitro and survival analysis demonstrated that high
expression of Talin-1 was associated with significantly
poorer OS and DMFS in patients with NPC. Further strati-
fied analysis revealed that high expression of Talin-1 was
associated with significantly poorer survival in patients
with stage III-IV disease. More importantly, multivariate
analysis showed that high expression of Talin-1 was an in-
dependent prognostic factor in NPC. These results sug-
gests that Talin-1 may be a useful prognostic biomarker for
NPC. However, further studies are needed to confirm these
findings in other cohorts of patients with NPC.
The mechanism of action of Talin-1 during the develop-
ment and progression of cancer is poorly characterized
and may be complex. Talin-1 may trigger a conform-
ational change in the extracellular domains of β-
Xu et al. BMC Cancer  (2015) 15:332 Page 9 of 10integrin, which may increase the affinity of β-integrin
for ECM proteins by linking the cytoplasmic domains
of integrin β subunits to actin filaments [34,35]. Previ-
ous studies had indicated that the activation of the
FAK/AKT pathway was associated with increased pro-
liferation, migration and invasion in a variety of tumors
[36-39]. Recently, Sakamoto and colleagues found that
overexpression of Talin-1 enhanced prostate cancer cell
adhesion, migration and invasion by stimulating FAK,
Src and GSK3β independently of integrin signaling and
also conferred resistance to anoikis [18]. Other researchers
reported that inhibition of the binding of Talin-1 to integ-
rin could prevent integrin activation and downregulate
downstream oncogenic signaling in vitro [33,40].
To date, the mechanisms leading to the high expres-
sion of Talin-1 in human cancers are not very clear.
Tang et al. found that TLN1 was overexpressed and as-
sociated with aggressiveness and metastasis in ovarian
serous carcinoma and microRNA-9 could inhibit Talin-1
expression by targeting its 3′untranslated region and
further led to the inhibition of the FAK/AKT pathway
[41]. The current study indicates that Talin-1 plays an
important role in the development and progression of
NPC. Further investigation of the function and mechan-
ism of action of Talin-1 may provide new opportunities
for therapeutic targeting of NPC and we will further ex-
plore the precise mechanisms by which Talin-1 mediates
progression and metastasis in NPC in a future study.
Conclusions
Talin-1 is upregulated at both the mRNA and protein
levels in NPC. High expression of Talin-1 was significantly
associated with poorer OS and DMFS in NPC, especially
in patients with advanced stage disease (stage III-IV).
Talin-1 may have potential as a novel prognostic bio-
marker and potential therapeutic target in NPC.
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